trial

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

NCTId NCT02477670
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 145 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2017-07-21
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
145 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2015-09-01
Primary completion
2017-07-21
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
AVP-786

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

0 total

Linked catalysts

1
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schi — primary completion2017-07-21

Facts & assertions

4 sourced
Enrollment
145
Phase
PHASE2
Primary Completion Date
2017-07-21
Status
COMPLETED
relationships
The graph out of here
drug
AVP-786
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication